The article discusses the poor performance of Pfizer Inc. in 2024 compared to other blue-chip stocks. Despite its past success with the COVID-19 vaccine, Pfizer's stock has been under pressure due to declining revenue opportunities. The company is preparing for patent expirations by launching new products.